Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 15 of the 29 sources its claims cite were checked for support.
Abstract
SagA promotes immunotherapy response: The gut microbiome can influence the treatment outcome for cancer patients receiving PD-L1 immunotherapy, but the mechanisms underlying favorable responses are unclear. Griffin et al . found that a particular type of bacteria called enterococci enhance anti–PD-L1 immunotherapy in mice (see the Perspective by Ansaldo and Belkaid). The researchers show that enterococci secrete an enzyme called SagA that breaks down components of the bacterial cell wall. This process results in the release of muramyl peptide fragments, which in turn act as stimulatory molecules to promote signaling of the innate immune sensor protein NOD2 and improved immunotherapy responses. —PNK
Overview
CoChat Summary
TL;DR
Enterococcus species that produce secreted NlpC/p60 peptidoglycan hydrolases (SagA orthologs) improve checkpoint inhibitor responses in mouse tumor models by generating NOD2-active muropeptides. Engineering SagA into non-active E. faecalis or probiotic L. lactis, or giving synthetic MDP-l,d, reproduced antitumor benefit with anti-PD-L1.
Key findings
- In antibiotic-pretreated C57BL/6 mice bearing B16-F10 melanoma, oral E. faecium Com15 plus anti-PD-L1 reduced tumor size at high and low antibody doses versus anti-PD-L1 alone; all three E. faecium isolates tested were active, while no E. faecalis strain was. Similar fecal CFU across strains indicated the effect was not due to bacterial load.
- Active species E. durans, E. hirae, and E. mundtii shared peptidoglycan remodeling signatures and SagA orthologs; C-terminal NlpC/p60 domains were >90% identical, E. gallinarum’s closest protein was 67% identical, and E. faecalis lacked direct orthologs. Recombinant orthologs showed d,l-endopeptidase activity producing GMDP.
- E. faecalis engineered to express SagA plus anti-PD-L1 reduced B16-F10 growth, and this required NOD2. L. lactis expressing wild-type SagA matched E. faecium benefit, whereas catalytically inactive C443A SagA did not.
- Synthetic NOD2-active MDP-l,d with anti-PD-L1 significantly inhibited tumors, unlike MDP-l,l; scRNA-seq showed more intratumoral T lymphocytes, cytotoxic gene enrichment, a Cx3cr1/Nr4a1 monocyte increase, and NF-κB/inflammatory signatures.
Methods
- Mouse tumor models: SPF C57BL/6 mice (Jackson) pretreated two weeks with ampicillin, colistin, and streptomycin, then orally supplemented with enterococci, implanted with B16-F10 melanoma and treated with anti-PD-L1; separate Taconic SPF mice without antibiotics; MCA205 fibrosarcoma with anti-PD-1 and MC38 colorectal carcinoma with anti-CTLA-4; B16-OVA for flow cytometry.
- Bacterial and biochemical assays: HPLC-MS peptidoglycan fragment profiling, genomic/sequence alignments for SagA orthologs, Western blot for secretion, recombinant hydrolase activity assays, fecal/tissue CFU, and 16S rRNA microbiome analysis.
- Immune profiling: tumor-infiltrating lymphocytes quantified by flow cytometry; CD45+ tumor cells from MDP stereoisomer-treated mice analyzed by scRNA-seq and gene set enrichment.
Limitations
- Stated: the authors could not detect SagA orthologs in clinical metagenomic datasets before checkpoint blockade, which they attribute to low E. faecium genome coverage (9.34%). They also note uncertainty for the secretion-deficient L. lactis SagA strain, suggesting either low secreted SagA was sufficient or non-secreted SagA leaked via lysis.
- Evident: efficacy and mechanism data come from mouse tumor models and bacterial/muropeptide interventions, not human clinical trials; antibiotic pretreatment substantially depletes resident microbiota, although a non-antibiotic SPF model was also used.
- Evident: microbiome analyses showed incomplete antibiotic clearance and shifts over time, and some differential OTUs appeared in only one cage per condition, limiting microbiome attribution.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 7 Not checked · 63 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple analyses of the commensal microbiome from human cohorts treated with immunotherapies targeting PD-1 have revealed that the bacterial genus Enterococcus is enriched in responding patients (12, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the paper’s results (our copy labels the section Abstract; page unavailable), Enterococcus faecium is listed among species more abundant in responders. The paper reports enrichment of that species in a metastatic melanoma cohort, not enrichment of the genus Enterococcus as a whole across human cohorts. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, the gut microbiota has emerged as a potent new factor associated with the efficacy of anti–CTLA4, anti–PD-1, and anti–PD-L1 treatment (8-14).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Partly supportedcites [8] Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther P-L, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350, 1079– 1084 (2015). 26541610 PMC4721659 sourceExperimental — accuracy not yet measured
The Abstract reports that gut microbiota composition influences the efficacy of CTLA-4 blockade, supporting the anti-CTLA-4 part of the sentence. The passages in our copy do not establish the same association for anti-PD-1 or anti-PD-L1 treatment, so this source does not support the full three-treatment claim. (LLM, conf=0.88)
- Partly supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 sourceExperimental — accuracy not yet measured
The supplied passages report that gut microbial composition influenced response to anti–PD-L1 treatment in mice. They discuss effects on the PD-1/PD-L1 axis more broadly, but do not report a direct anti–PD-1 treatment test; the CTLA-4 passage says the principles *could* apply to that pathway. Thus this source supports the anti–PD-L1 part, but not the claim that microbiota is established as associated with efficacy for all three treatments. (LLM, conf=0.88)
- Supportedcites [10] Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY, Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 19, 848– 855 (2017). 28923537 PMC5602478 source
The Introduction reports that gut microbiota influence responses to anti-PD-L1 and anti-CTLA4 therapy in mouse models. The Discussion reports gut microbial species associated with clinical response to anti-PD1 alone and combined anti-PD1/anti-CTLA4 therapy in melanoma patients. Together, these passages support the broad association claimed; page numbers are not provided in our copy. (LLM, conf=0.92)
- Supportedcites [11] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza I source
The paper reports an association between gut microbiome composition and anti-PD-1 response in melanoma patients, cites a similar finding in a small anti-CTLA-4 cohort, and reports improved anti-PD-L1 response in mice receiving fecal transplants from anti-PD-1 responders. These passages support the broad association claimed, although the evidence comes from different populations and study designs. (LLM, conf=0.87)
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
The paper reports an association between gut microbiota and anti–PD-1 response in metastatic melanoma patients, and its mouse experiments show differing anti–PD-L1 efficacy by microbiota (Abstract; Fig. 3F discussion; page unavailable). It included four anti–CTLA-4 recipients but reports no separate microbiota–efficacy association for that treatment. The anti–PD-L1 result is in mice, not patients. (LLM, conf=0.88)
- Supportedcites [14] Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, Weber JS, Osman I, Ahn J, Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019). 31597568 PMC6785875 source
The Background reports gut-microbiota effects on anti-CTLA-4 and anti-PD-L1 immunotherapy in mice and an association with clinical response in human melanoma patients. The Discussion describes associations with response to anti-PD-1 and anti-CTLA-4 treatment in melanoma patients. Together, these passages support the broad association attributed to this source. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“consistent with enhanced priming of a tumor antigen-specific immune response (9, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 source
The paper reports greater expansion of tumor-antigen-specific CD8+ T cells in tumor-draining lymph nodes and describes differences in T-cell priming in vivo (passages [1] and [2], page unavailable). This supports the cited interpretation that an increase in antigen-specific CD8+ T cells is consistent with enhanced priming. The paper studied SIY-specific cells; the citing paper’s OVA-specific observation is not itself attributed to this source. (LLM, conf=0.88)
- Supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 source
The passage describing the mouse tumor experiment reports more SIY-specific CD8+ T cells and explicitly interprets this as increased priming of tumor antigen-specific CD8+ T cells. The citation is attached to that interpretation, not to the citing study’s OVA-specific measurement. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Significant enrichment of hallmark gene sets (33) for inflammatory response and NF-κB signaling were found in the MDP-l,d dataset (Table S8).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [33] Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P, The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417– 425 (2015). 26771021 PMC4707969 source
The citation (33) is attached to 'hallmark gene sets' — an identification of the resource the citing authors ran enrichment against — not to their own MDP-l,d result. Our copy is exactly that source: the DISCUSSION states the hallmarks are released as the H Collection in MSigDB v5.0, every set name starting with HALLMARK, with Table 1 listing all 50 hallmarks and their descriptions; the RESULTS (Analysis of necrosis in glioblastoma) treat NFκB signaling as one of the biological themes covered, and the protein-phenotype validation section documents the immune/inflammatory hallmarks (IL6 JAK STAT3, IL2 STAT5 signaling). No passage of our copy reports anything about an 'MDP-l,d' dataset, which is consistent with that being the citing authors' own analysis rather than something attributed here. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We further confirmed that SagA orthologs are found in humans through alignment of the SagA NlpC/p60 domain with genomes within the Human Microbiome Project (24) (Fig. 2C, Table S5).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [24] Consortium THMJRS, A catalog of reference genomes from the human microbiome. Science. 328, 994– 999 (2010). 20489017 PMC2940224 source
The citation identifies the Human Microbiome Project genomes used for the citing authors’ alignment; the SagA result is presented as the citing authors’ own finding. The source’s Reference genome progress section describes the HMP-sequenced genomes, and its Data release section says their sequences and annotations were made available. (LLM, conf=0.91)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
54 more claims
Create a free account to see all 78 claims and to verify the 14 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, cause-effect relationships between the prevalence or relative abundance of particular taxa, and clinical regression or progression, have been shown in animal models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several probiotics or their products can inhibit tumor development by suppressing inflammation and promoting anti-tumor immune responses6,7.”
From Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Enterococcus expressed and secreted orthologs NlpC/p60 PG hydrolase SagA and could promote expression of the innate immune sensor protein nucleotide-binding oligomerization domain containing 2 (NOD2) and augment ICI antitumor efficacy [109] (Fig. 5F).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [109]
In the citing paper
“Thus, the peptidoglycan hydrolase SagA from Enterococcus faecium can be transferred into Lactococcus lactis to generate a probiotic strain that stimulates innate immune responses via NOD2 activation and promotes ICI antitumor activity in mice.26”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies
Nguyen, L.-T., Schmidt, H. A., von Haeseler, A., & Minh, B. Q. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msu300 · Cited by 26,046
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
“A recent study has shed some light: certain strains of Enterococcus (and other bacteria) express a peptidoglycan hydrolyase called SagA that releases mucopeptides from the bacterial wall, which can then circulate systemically and activate the NOD2 pattern receptor, which in turn can enhance T-cell responses and the ef…”
BackgroundGut microbiome and health: mechanistic insights
de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022) · Gut · doi:10.1136/gutjnl-2021-326789 · Cited by 2,388
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Jiang, S.-S., Xie, Y.-L., Xiao, X.-Y., Kang, Z.-R., Lin, X.-L., Zhang, L., Li, C.-S., Qian, Y., Xu, P.-P., Leng, X.-X., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.04.010 · Cited by 419
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Fong, W., Li, Q., Ji, F., Liang, W., Lau, H. C. H., Kang, X., Liu, W., To, K. K.-W., Zuo, Z., Li, X., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-329543 · Cited by 312
“13 These findings have high-lighted the potential of leveraging probiotics or bacteria-based therapeutics as an adjuvant to improve cancer immunotherapy.”
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Inflammation: the incubator of the tumor microenvironment
Denk, D., & Greten, F. R. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.07.002 · Cited by 273
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
Park, J. S., Gazzaniga, F. S., Wu, M., Luthens, A. K., Gillis, J., Zheng, W., LaFleur, M. W., Johnson, S. B., Morad, G., Park, E. M., et al. (2023) · Nature · doi:10.1038/s41586-023-06026-3 · Cited by 191
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 176
“In a recent study, NOD2-active muropeptides generated by active enterococci with orthologs of the NlpC/ p60 peptidoglycan hydrolase SagA were shown to improve the efficacy of ICI immunotherapy [310].”
BackgroundModulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 197
Dietary Lactobacillus -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
Kawanabe-Matsuda, H., Takeda, K., Nakamura, M., Makino, S., Karasaki, T., Kakimi, K., Nishimukai, M., Ohno, T., Omi, J., Kano, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0929 · Cited by 150
“These effects were postulated to be mediated by bacterial-derived metabolites or cell wall components [such as short chain fatty acids (14), inosine (15), and peptidoglycan (16)].”
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Liu, Y., Wong, C. C., Ding, Y., Gao, M., Wen, J., Lau, H. C.-H., Cheung, A. H. K., Huang, D., Huang, H., & Yu, J. Q. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01695-w · Cited by 151
“Gut commensals have been shown to be crucial in mediating effective immunotherapeutic responses 11–15 , and fecal microbiota transplantation and probiotic cocktails 16 have been proposed as potential adjuvants for ICB therapy.”
Intestinal bacteria and colorectal cancer: etiology and treatment
Dougherty, M. W., & Jobin, C. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185028 · Cited by 159
Lang, T., Zhu, R., Zhu, X., Yan, W., Li, Y., Zhai, Y., Wu, T., Huang, X., Yin, Q., & Li, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-40439-y · Cited by 133
Choi, Y., Lichterman, J. N., Coughlin, L. A., Poulides, N., Li, W., Del Valle, P., Palmer, S. N., Gan, S., Kim, J., Zhan, X., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo2003 · Cited by 132
“S1B), including taxa previously reported to be associated with positive ICT responses or implicated in host anticancer immune responses: Bifidobacterium pseudolongum (9), Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium adolescentis (13), Bacteroidetes thetaiotamicron (7, 24), Enterococcus faecalis (22,…”
InfluentialMicrobial transmission in the social microbiome and host health and disease
Sarkar, A., McInroy, C. J. A., Harty, S., Raulo, A., Ibata, N. G. O., Valles‐Colomer, M., Johnson, K. V. ‐., Brito, I., Henrich, J., Archie, E. A., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.014 · Cited by 151
Gao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
The gut microbiota in cancer immunity and immunotherapy
Xie, M., Li, X., Lau, H. C.-H., & Yu, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01326-2 · Cited by 138
Gao, G., Shen, S., Zhang, T., Zhang, J., Huang, S. W., Sun, Z., & Zhang, H. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104533 · Cited by 124
Gut microbial DL-endopeptidase alleviates Crohn’s disease via the NOD2 pathway
Gao, J., Zhao, X., Hu, S., Huang, Z., Hu, M., Jin, S., Lu, B., Sun, K., Wang, Z., Fu, J., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.08.002 · Cited by 113
Gupta, K. H., Nowicki, C. A., Giurini, E. F., Marzo, A. L., & Zloza, A. (2021) · Vaccines · doi:10.3390/vaccines9121497 · Cited by 120
“typhimurium (χ4550) Hepatocellular carcinoma I [193]”
Aghamajidi, A., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14153563 · Cited by 110
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Xie, J., Liu, M., Deng, X., Tang, Y., Zheng, S., Ou, X., Tang, H., Xie, X., Wu, M., & Zou, Y. (2024) · iMeta · doi:10.1002/imt2.156 · Cited by 109
Microbiota-driven mechanisms at different stages of cancer development
Ivleva, E., & Grivennikov, S. I. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100829 · Cited by 103
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citationThe human microbiome and cancer: a diagnostic and therapeutic perspective
Kandalai, S., Li, H., Zhang, N., Peng, H., & Zheng, Q. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2240084 · Cited by 101
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 108
Messengers From the Gut: Gut Microbiota-Derived Metabolites on Host Regulation
Li, C., Liang, Y., & Qiao, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.863407 · Cited by 107
Li, X., Shang, S., Wu, M., Song, Q., & Chen, D. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217096 · Cited by 92
Microbiota-driven antitumour immunity mediated by dendritic cell migration
Lin, Y.-T., Fukuoka, S., Koyama, S., Motooka, D., Tourlousse, D. M., Shigeno, Y., Matsumoto, Y., Yamano, H., Murotomi, K., Tamaki, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09249-8 · Cited by 91
Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy
Yang, Y., An, Y., Dong, Y., Chu, Q., Wei, J., Wang, B., & Cao, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104967 · Cited by 90
The gut microbiome and cancer response to immune checkpoint inhibitors
Gazzaniga, F. S., & Kasper, D. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184321 · Cited by 92
The heightened importance of the microbiome in cancer immunotherapy
Villemin, C., Six, A., Neville, B. A., Lawley, T. D., Robinson, M. J., & Bakdash, G. (2023) · Trends in Immunology · doi:10.1016/j.it.2022.11.002 · Cited by 73
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
“This induces the expression of Illb and Nlrp3 genes, activates the immune system, and enhances the effect of anti-cancer immunotherapy 65 .”
Jang, K. K., Heaney, T., London, M., Ding, Y., Putzel, G., Yeung, F., Ercelen, D., Chen, Y.-H., Axelrad, J., Gurunathan, S., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.08.002 · Cited by 70
Self-citationInfectious diseases, autoantibodies, and autoimmunity
Johnson, D., & Jiang, W. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102962 · Cited by 83
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 83
“One study recently observed that bacteria expressing SagA improve the efficacy of checkpoint inhibitor therapy in animal models [186].”
BackgroundSegers, A., & de Vos, W. M. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2023.05 · Cited by 71
The role of the gut microbiota in tumor, immunity, and immunotherapy
Xie, Y., & Liu, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410928 · Cited by 77
Su, Y., Xu, W., Wei, Q., Ma, Y., Ding, J., & Chen, X. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.01.024 · Cited by 68
Zhong, H., Jiang, J., Hussain, M., Zhang, H., Ling, C., & Guan, R. (2025) · Advanced Science · doi:10.1002/advs.202500304 · Cited by 84
Integrating the gut microbiome and pharmacology
Verdegaal, A. A., & Goodman, A. L. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8357 · Cited by 71
“It may also include the activity of an Enterococcus enzyme, SagA, which leads to production of immunostimulatory muropeptide fragments that enhance immune checkpoint inhibitor efficacy ( 161 ).”
BackgroundCao, C., Yue, S., Lü, A., & Liang, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107321 · Cited by 67
Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context
Liu, Y., Niu, L., Li, N., Wang, Y., Liu, M., Su, X., Bao, X., Yin, B., & Shen, S. (2023) · Advanced Science · doi:10.1002/advs.202205641 · Cited by 60
How microbiota improve immunotherapy
Ansaldo, E., & Belkaid, Y. (2021) · Science · doi:10.1126/science.abl3656 · Cited by 54
Zhang, X., Feng, H., He, J., Liang, X., Zhang, N., Shao, Y., Zhang, F., & Lu, X. (2022) · Pest Management Science · doi:10.1002/ps.6846 · Cited by 56
Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
Ohtani, N., Kamiya, T., & Kawada, N. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000241 · Cited by 63
Cao, F., Jin, L., Zhang, C., Gao, Y., Qian, Z., Wen, H., Yang, S., Ye, Z., Hong, L., Huang, Y., et al. (2023) · Advanced Materials · doi:10.1002/adma.202304257 · Cited by 66
The danger theory of immunity revisited
Kroemer, G., Montégut, L., Kepp, O., & Zitvogel, L. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01102-9 · Cited by 58
“Some Enterococci (such as Enterococcus faecium, Enterococcus durans , Enterococcus hirae and Enterococcus mundtii ) shed enzymes that generate muropeptides that act on the PRR NOD2, thereby augmenting the antitumour efficacy of PD1 blockade 158 .”
Yin, R., Wang, T., Sun, J., Dai, H., Zhang, Y., Liu, N., & Liu, H. (2024) · Advanced Science · doi:10.1002/advs.202405781 · Cited by 80
Lu, S., Xu, J., Zhao, Z., Guo, Y., Zhang, H., Jurutka, P. W., Huang, D., Cao, C., & Cheng, S. (2023) · Food & Function · doi:10.1039/d3fo02018e · Cited by 59
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
Tumor microbiome metabolism: A game changer in cancer development and therapy
Zhou, X., Kandalai, S., Hossain, F., & Zheng, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933407 · Cited by 57
Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses
Sardar, P., Beresford-Jones, B. S., Xia, W., Shabana, O., Suyama, S., Ramos, R. J. F., Soderholm, A. T., Tourlomousis, P., Kuo, P., Evans, A. C., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01930-y · Cited by 49
“Other microbiota-derived metabolites, including Bifidobacterium inosine 26 , Enterococcus muropeptides 27 and bacterial flagellin 28 , have also been implicated in modulating ICI treatment response.”
Zheng, H.-H., Du, C.-T., Yu, C., Tang, X.-Y., Huang, R., Zhang, Y., Gao, W., & Xie, G.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810928 · Cited by 54
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
Song, Y., Lau, H. C.-H., Zhang, X., & Yu, J. Q. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0394 · Cited by 78
Gao, J., Wang, L., Jiang, J., Xu, Q., Zeng, N., Lu, B., Yuan, P., Sun, K., Zhou, H., & He, X. (2023) · Nature Communications · doi:10.1038/s41467-023-38950-3 · Cited by 58
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
“Besides that, Griffin et al. 275 also re-ported a novel kind of immunotherapy adjuvant, i . e ., Enterococci with specialized peptidoglycan remodeling abilities, which could secrete the NlpC/p60 peptidoglycan hydrolase SagA orthologs to generate immune-active muropeptides to promote checkpoint…”
BackgroundThe impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
“In addition, the same bacteria may show different characteristics due to environmental changes or the composition of other bacteria, and different bacteria may share similar metabolic pathways with similar functions [47, 193].”
BackgroundXia, L., Zhu, X., Wang, Y., & Lü, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217123 · Cited by 56
Peptidoglycan NlpC/P60 peptidases in bacterial physiology and host interactions
Griffin, M. E., Klupt, S., Espinosa, J., & Hang, H. C. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2022.11.001 · Cited by 44
Self-citationData-driven prediction of colonization outcomes for complex microbial communities
Wu, L., Wang, X.-W., Tao, Z., Wang, T., Zuo, W., Zeng, Y., Liu, Y.-Y., & Dai, L. (2024) · Nature Communications · doi:10.1038/s41467-024-46766-y · Cited by 44
Gut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
Liu, N., Chen, L., Yan, M., Tao, Q., Wu, J., Chen, J., Chen, X., Zhang, W., & Peng, C. (2023) · Research · doi:10.34133/research.0127 · Cited by 41
“(b) In regard to enzymes or surface antigen structures, the enzyme SagA expressed by Enterococcus faecalis activated innate immunity by releasing peptidoglycan fragments, inducing a microenvironment favorable for immunotherapy and that enhanced the immunotherapeutic effects [13].”
BackgroundInfluence of the gut microbiota on immune cell interactions and cancer treatment
Liu, C., Fu, L., Wang, Y., & Yang, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05709-3 · Cited by 50
Gronke, K., Nguyen, M. T., Fuhrmann, H., de Souza, N. S., Schumacher, J., Pereira, M. S., Löschberger, U., Brinkhege, A., Becker, N. J., Yang, Y., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adj6294 · Cited by 45
Postbiotics as potential new therapeutic agents for sepsis
Lou, X., Xue, J., Shao, R., Mo, C., Wang, F., & Chen, G. (2023) · Burns & Trauma · doi:10.1093/burnst/tkad022 · Cited by 38
“Microbiota with unique peptidoglycan remodeling activity and muropeptide-based treatments have both been proposed as potential cancer immunotherapy enhancements and next-generation adjuvants [118].”
BackgroundGut microbial metabolites in cancer therapy
Song, P., Peng, Z., & Guo, X. (2025) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.06.016 · Cited by 38
Wang, B., Qiu, Y., Xie, M., Huang, P., Yu, Y., Sun, Q., Shangguan, W., Li, W., Zhu, Z., Xue, J., et al. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03372-8 · Cited by 42
Chen, C., Su, Q., Zi, M., Hua, X., & Zhang, Z. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00818-3 · Cited by 51
“…with L. lactis expressing wild-type SagA demonstrated tumor growth inhibition comparable to that of E. faecium -treated animals, effectively augmenting the activity of anti-PD-L1 antibodies to a similar extent as natural SagA-expressing Enterococcus strains in MC38 CRC allograft mice 175 .”
Chemoproteomics reveals microbiota-derived aromatic monoamine agonists for GPRC5A
Zhao, X., Stein, K. R., Chen, V., Griffin, M. E., Lairson, L. L., & Hang, H. C. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01328-z · Cited by 40
Self-citationZhu, R., Yuan, W., Xia, A., Sun, X., Yan, W., Wu, T., Wang, G., Li, Y., Yin, Q., & Li, Y. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407685 · Cited by 43
Microbiota-mediated mechanisms of mucosal immunity across the lifespan
Iliev, I. D., Blander, J. M., Collins, N., Guo, C., Longman, R., Sonnenberg, G. F., Zeng, M. Y., & Artis, D. (2025) · Nature Immunology · doi:10.1038/s41590-025-02281-w · Cited by 66
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 45
“faecalis, could augment immunotherapy efficacy by expressing and secreting the peptidoglycan hydrolase secreted antigen A (SagA) which generates immune-active muropeptides to activate NOD2-dependent NF-κB- and MAPKmediated signaling of pro-inflammatory genes [117].”
BackgroundDai, H., Han, J., Wang, T., Yin, W., Chen, Y., & Liu, H. (2023) · Natural Product Reports · doi:10.1039/d2np00075j · Cited by 39
Wang, W., Lu, G., Wu, X., Wen, Q., & Zhang, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030780 · Cited by 38
“faecalis was sufficient to promote anti-PD-1 antitumor efficacy [79].”
Qiao, G., Li, H., Pan, X., Xie, P., Peng, R., Huang, X., He, M., Jiang, J., & Chu, X. (2024) · Science Advances · doi:10.1126/sciadv.adk7955 · Cited by 39
Lu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 45
Stubbendieck, R. M., Dissanayake, E., Burnham, P. M., Zelasko, S. E., Temkin, M. I., Wisdorf, S. S., Vrtis, R. F., Gern, J. E., & Currie, C. R. (2023) · mBio · doi:10.1128/mbio.00464-23 · Cited by 37
“The NOD2 sensor is activated by N -acetylglucosamine muramyl dipeptides generated from peptidoglycan by the D , L -endopeptidase activity of enterococcal SagA, suggesting that the microbiota can modulate responses to immunotherapy (65).”
Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway
Hu, M., Xu, Y., Wang, Y., Huang, Z., Wang, L., Zeng, F., Qiu, B., Liu, Z., Yuan, P., yu, W., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-332891 · Cited by 35
“21 We and others have previously shown that specific muramyl peptides, such as GlcNAc-MDP and MDP, produced by peptidoglycan hydrolase DL-endopeptidase, can improve cancer immunotherapy, 22 protect against colitis and inhibit the colitis-cancer transformation via the NOD2 pathway.”
Translating Microbiome Research From and To the Clinic
Zhang, Z. J., Lehmann, C. J., Cole, C. G., & Pamer, E. G. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041020-022206 · Cited by 33
Sepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Chen, Q., Zhu, Y., Wang, K., Wang, X., Zhang, Y., Zhou, M., Du, J., Qu, X., Shi, Z., Zhang, Y., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101994 · Cited by 38
Choi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · BMC Genomics · doi:10.1186/s12864-023-09945-7 · Cited by 40
Zhao, H., Wang, D., Zhang, Z., Xian, J., & Bai, X. (2022) · Molecules · doi:10.3390/molecules27154799 · Cited by 38
Contribution of the microbiome for better phenotyping of people living with obesity
Ciaula, A. D., Bonfrate, L., Khalil, M., Garruti, G., & Portincasa, P. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09798-1 · Cited by 41
Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors
Wang, J., Zhu, N., Su, L., & Yang, R. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216582 · Cited by 37
Yarahmadi, A., Zare, M. A., Aghayari, M., Afkhami, H., & Jafari, G. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01622-w · Cited by 33
Human Microbiome and Its Medical Applications
Zhang, Y., Zhou, L., Xia, J., Dong, C., & Luo, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.703585 · Cited by 32
“In addition to direct enrichment to tumor sites, engineered microbes can also remotely express relevant antigens or immunomodulatory substances, thereby enhancing tumor therapeutic effects (Chung et al., 2021; Griffin et al., 2021).”
BackgroundYin, R., Wang, T., Dai, H., Han, J., Sun, J., Liu, N., Dong, W., Jin, Z., & Liu, H. (2023) · Protein & Cell · doi:10.1093/procel/pwad016 · Cited by 36
“It has been verified that the d-isoGln at the end of the peptide in MDP is essential for its specific activation of NOD2 pathway (Griffin et al., 2021).”
BackgroundIntestinal dysbiosis and colorectal cancer
Kang, Z., Jiang, S., Fang, J., & Chen, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003617 · Cited by 38
“[117] This demonstrates the potential for bacterial components to enhance immunotherapy outcomes in CRC by increasing immune activity within the tumor.”
The role of the sex hormone-gut microbiome axis in tumor immunotherapy
Wang, L., Tang, L., Zhai, D., Song, M., Li, W., Xu, S., Jiang, S., Meng, H., Liang, J., Wang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185035 · Cited by 34
Metadata
- Authors
- Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C.
- Affiliations
- Scripps Research Institute (US)
- Rockefeller University (US)
- Rise Therapeutics, 1405 Research Blvd. Suite 220, Rockville, MD 20850, USA.
- Corresponding author
- Hang, Howard C.
- ORCID
- Venue
- Science
- Published
- 2021-08-27
- Volume
- 373
- Issue
- 6558
- Pages
- 1040-1046
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9503018
- OpenAlex
- W3194929095
- Cited by
- 366
- References
- 75
- Citations by year
- 2026: 69 · 2025: 71 · 2024: 83 · 2023: 80 · 2022: 52 · 2021: 10
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1R01CA245292-01, A1070084)
- Melanoma Research Foundation (Career Development Award)
- ASCRS Research Foundation (HCFR-19-03-02)
- Hope Funds for Cancer Research (HCFR-19-03-02)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- Enterococcus, sagas, peptidoglycan remodeling, cancer immunotherapy, PD-L1 blockade, gut microbiota, muramyl peptides, NOD2 signaling, innate immunity, bacterial cell wall degradation
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Bacterial Proteins, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, N-Acetylmuramoyl-L-alanine Amidase, Peptide Fragments, Peptidoglycan, Enterococcus faecalis, Signal Transduction, Enterococcus, Enterococcus faecium, Probiotics, Mice, Nod2 Signaling Adaptor Protein, Bacterial Load, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.